Coronary artery disease: an inflammatory or infectious process J. JahnK. DalhoffH.A. Katus Pages: I59 - I64
MERIT-HF mortality and morbidity data Å. HjalmarsonB. Fagerbergon behalf of the MERIT-HF Study Group Pages: I98 - I103
Beta-blockers: recognising the assets in relation to coronary artery disease M.J. Kendall Pages: I31 - I36
Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? Å. Hjalmarson Pages: I41 - I45
Coronary artery disease – free radical damage, antioxidant protection and the role of homocysteine S.R.J. Maxwell Pages: I65 - I71
MERIT-HF – description of the trial J. Wikstrandon behalf of the MERIT-HF Study Group Pages: I90 - I97
Treatment of heart failure with beta-blockers. Mechanisms and results M. BöhmC. Maack Pages: I15 - I24